Shares of Scholar Rock Holdings jumped Wednesday after the biopharmaceutical firm reported positive results from a ...

Scholar Rock said on Wednesday a combination of its experimental drug and Eli Lilly's weight-loss treatment Zepbound helped overweight patients preserve significantly more lean mass in a mid-stage ...

In combination with Eli Lilly’s tirzepatide, marketed as Zepbound for obesity, Scholar Rock’s monolonal antibody helped ...

Scholar Rock's apitegromab helped preserve muscle mass during tirzepatide-induced weight loss, improving overall body ...

Eli Lilly just dropped $1 billion—plus a $300 million bonus if trials go well—on gene therapy firm Verve, aiming to spice up ...

(Reuters) -Current weight-loss methods such as lifestyle changes, surgery, and popular therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss that can ...

On the sidelines of BIO2025, Julie Gilmore, head of Lilly Gateway Labs, shares her thoughts on the $1.3 billion Verve Therapeutics buy, where Lilly’s therapeutic puck is potentially going and how the ...

Scholar Rock’s investigational spinal muscular atrophy drug helped patients taking Eli Lilly’s obesity blockbuster Zepbound ...

A new study reveals that bariatric surgery results in significantly greater weight loss compared to popular GLP-1 drugs.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Eli Lilly and Company (NYSE:LLY) is one of Best Dividend Stocks to Buy for Dependable Dividend Growth. According to Adam ...

US Big Pharma firm Eli Lilly & Co. agreed to buy gene-editing biotech company Verve Therapeutics Inc. for $1.3 billion as the ...